Savient Pharmaceuticals, Inc. (SVNT)

HEALTH CARE: PHARMACEUTICALS
SIC: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

ONE TOWER CENTER EAST BRUNSWICK, NJ 08816

Savient Pharmaceuticals, Inc. (Savient) is a specialty pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that address unmet medical needs. The Company markets one product in the United States, Oxandrin, an oral anabolic steroid. Oxandrin is marketed to physicians in the human immunodeficiency virus (HIV) and oncology areas. It also markets more than 100 pharmaceutical products in oral liquid form in the United Kingdom and some European Union countries through its subsidiary, Rosemont Pharmaceuticals Limited (Rosemont). It also has one compound in Phase III clinical development, Puricase (PEG-uricase), indicated for the treatment of symptomatic gout in patients in whom conventional therapy is contraindicated or has been ineffective. In August 2006, Savient sold Rosemont to an entity affiliated with Close Brothers Private Equity. In July 2005, Savient divested its global manufacturing biologics business.

Are you looking for this stock instead?

View SEC Filings from SVNT instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding SVNT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SVNT BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

THOMPSON VIRGIL

  • Director
0 2013-12-04 0

JAEGER STEPHEN O

  • Director
0 2013-10-17 0

CONSTANTINE GINGER

  • Director
0 2013-10-16 0

BAHRT KENNETH SVP, CHIEF MEDICAL OFFICER

  • Officer
100,000 2013-10-15 0

YACHMETZ PHILIP K CO-PRESIDENT AND CBO

  • Officer
90,545 2013-10-15 0

CROWLEY RICHARD CO-PRESIDENT AND COO

  • Officer
171,750 2013-10-15 0

GIONCO DAVID CHIEF ACCOUNTING OFFICER

  • Officer
35,764 2013-10-15 0

HAMILL JOHN CO-PRESIDENT AND CFO

  • Officer
66,667 2013-10-15 0

FERRARI LOUIS PRESIDENT AND CEO

  • Officer
  • Director
307,439 2013-05-22 0

VEITCH DAVID PRESIDENT

  • Officer
  • SAVIENT PHARMA IRELAND LIMITED
0 2013-03-05 0

MEEKER DAVID P

  • Director
12,644 2013-01-07 0

SAVAGE ROBERT G.

  • Director
16,149 2012-12-05 0

NORTON DAVID Y

  • Director
69,284 2012-07-09 0

OWEN WILLIAM F

  • Director
56,631 2012-05-22 0

ZUERBLIS KENNETH J EVP, CHIEF FINANCIAL OFFICER

  • Officer
0 2012-02-01 0

JOHNSON JOHN CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
252,350 2012-01-03 0

HELLER ALAN L

  • Director
40,179 2011-09-15 0

SIMON LEE S

  • Director
29,179 2011-05-26 0

HAMELIN PAUL PRESIDENT

  • Officer
124,765 2011-02-14 0

CONRAD HERBERT J

  • Director
28,501 2010-06-08 0

KLEIN JOSEPH III

  • Director
17,388 2010-06-08 0

HOROWITZ ZEBULUN D SVP - CHIEF MEDICAL OFFICER

  • Officer
144,683 2009-02-17 0

HAYDEN BRIAN J

  • FORMER CFO
No longer subject to file 2009-02-17 0

LAMM ROBERT

  • FORMER SVP, QA/RA
49,186 2009-02-17 0

CLEMENT CHRISTOPHER G

  • FORMER PRESIDENT & CEO
276,511 2008-12-08 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments